Sign in

    Anthony

    Managing Director and Senior Equity Research Analyst at Raymond James

    Anthony Petrone is a Managing Director and Senior Equity Research Analyst at Raymond James, specializing in healthcare and medical technology. He covers major companies such as Medtronic, Boston Scientific, Hologic, and Zimmer Biomet, consistently earning recognition for his accurate investment calls and insightful forecasts; according to TipRanks, Anthony maintains an average success rate of 67% and has generated a 14% average annual return on his recommendations. With a career spanning over two decades, Anthony previously served at Jefferies and Bank of America Merrill Lynch before joining Raymond James in 2013, building a reputation for analytical rigor and industry expertise. He holds FINRA Series 7, 63, 86, and 87 registrations, and has received multiple awards for excellence in research from Institutional Investor and other industry organizations.

    Anthony's questions to Trevi Therapeutics (TRVI) leadership

    Anthony's questions to Trevi Therapeutics (TRVI) leadership • Q1 2025

    Question

    Anthony, on behalf of Ryan Deschner, asked if the company had observed any trends in the RIVER study data related to patient baseline characteristics, such as background therapies or initial disease etiology.

    Answer

    Chief Development Officer Dr. James Cassella stated that while the team is analyzing all the data, he did not have a definitive answer on such trends at this time. Executive Jennifer Good added that the drug demonstrated a strong effect across the board, making it difficult to identify specific subgroups where it worked differently.

    Ask Fintool Equity Research AI

    Anthony's questions to Wave Life Sciences (WVE) leadership

    Anthony's questions to Wave Life Sciences (WVE) leadership • Q1 2025

    Question

    An analyst from Raymond James asked which specific biomarkers the company plans to report from the ENLIGHT trial for its WVE-007 obesity candidate.

    Answer

    President and CEO Dr. Paul Bolno stated that the disclosed biomarkers for the upcoming readout will include changes in body weight and levels of Activin E (the protein product of the INHBE gene). He explained that tracking Activin E will serve as a key measure of target engagement and will also help inform the durability of the drug's effect over time. He mentioned that other exploratory biomarkers are also being assessed in the study.

    Ask Fintool Equity Research AI